To observe the effect of amikacin sulfate combined with Guizhi Fuling capsule in the treatment of the chronic pelvic inflammation complicated with pelvic effusion.
A total of 134 patients of the chronic pelvic inflammation complicated with pelvic effusion in our hospital from August 2014 to February 2017 were selected and divided into combination therapy group and single drug group, 67 cases each group. The combination therapy group was treated with amikacin sulfate combined with Guizhi Fuling capsule, and the single drug group was treated with amikacin sulfate alone. The clinical outcomes, pain score, symptom relief time, pelvic effusion diamete, days of hospitalization, WHOQOL-BREF score, inflammatory factor levels, adverse drug reactions, and recurrence rate were compared.
After 3 days and 7 days of treatment, the cure rate, effective rate and total effective rate in combination therapy group were higher than those in single drug group, the difference was statistically significant (P<0.05). In the combination therapy group, the pain score, symptom relief time, pelvic effusion diamete and days of hospitalization were less than those in single drug group significantly (P<0.05). The health status, quality of life, self-perception and daily life score of the WHOQOL-BREF score in the combination therapy group were higher than those in single drug group significantly (P<0.05). The levels of CRP and TNF-α in the combination therapy group were lower than those in single drug group, and the IL-2 was higher than that in single drug group significantly (P<0.05). The incidence of adverse drug reactions in the combination therapy group was similar to that in single drug group, and the recurrence rate was lower than that of single drug group significantly (P<0.05).
Amikacin sulfate combined with Guizhi Fuling capsule is effective in the treatment of chronic pelvic inflammatory complicated with pelvic effusion, the symptoms are relieved, the days of hospitalization is short, alleviates the inflammatory reaction, and effectively improves the quality of life, adverse drug reactions and recurrence rate are low, which is valuable recommended for clinical widely use.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |